Bayosthiti is an AI‑first molecular diagnostics company that generates India‑specific transcriptomic data using its patented Barcode‑Integrated Reverse Transcription (BIRT) technology. The end‑to‑end platform converts RNA samples into actionable health insights and delivers personalized care recommendations through its digital portals for patients (Bayosthiti Ayu) and clinicians (Bayosthiti Pragyan), targeting high‑impact areas such as maternal health, infectious disease, cardiovascular disease, and oncology.
Funding
Funding not disclosed
Founders
Product
Problem
India’s healthcare decisions rely on diagnostic tools built from Western-centric genetic data, which do not reflect the country’s diverse population. This data gap leads to less accurate diagnoses and ineffective treatments, especially for prevalent conditions such as maternal health issues, infectious diseases, heart disease, and cancer.
Solution
Bayosthiti addresses this gap by offering an AI‑first molecular diagnostics platform that generates India‑specific transcriptomic data through its patented Barcode‑Integrated Reverse Transcription (BIRT) technology. The platform provides an end‑to‑end sample‑to‑insight workflow, converting raw RNA samples into actionable health insights without the need for extensive laboratory infrastructure. AI algorithms analyze the generated data to deliver personalized, proactive care recommendations that span from early‑life health monitoring to peak performance and healthy aging. By integrating these insights into a digital health interface, Bayosthiti enables both patients and clinicians to make data‑driven decisions tailored to the Indian genetic landscape.
Target Audience
Primary customers are Indian patients seeking personalized health insights and healthcare professionals (clinicians, labs, and wellness providers) who require accurate, locally relevant molecular diagnostics.
Features
- BIRT technology that lowers the cost of high‑throughput RNA sequencing for large‑scale population screening
- India‑specific transcriptomic database built from diverse regional samples
- AI‑driven analytics pipeline that translates raw molecular data into personalized health recommendations
- End‑to‑end sample‑to‑insight workflow, eliminating the need for multiple third‑party lab services
- Digital health portal (Bayosthiti Ayu for patients, Bayosthiti Pragyan for professionals) delivering real‑time reports and care plans
- Focus on high‑impact health areas such as maternal and infant health, infectious disease, antimicrobial resistance, cardiovascular disease, and oncology